NSCLC patients with elevated expression of IGF-1R show poor responses to EGFR-TKIs treatment, strongly suggesting that activation of the IGF-1R pathway is relevant to resistance against EGFR-TKIs (27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.